Phase III Randomized, Controlled Study of Blinatumomab Alternating with Low-Intensity Chemotherapy Versus Standard of Care for Older Adults with Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia with Safety Run-In
Details
The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.
Eligibility
You can join if...
AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.
Inclusion Requirements
You can participate in this study if you are a male or female ages ≥ 55 years at the time of informed consent.
Exclusion Requirements.
You cannot participate in this study if you are a female who is pregnant or breastfeeding or planning to become pregnant